236 related articles for article (PubMed ID: 2160820)
1. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
[TBL] [Abstract][Full Text] [Related]
2. SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H+ + K+)-ATPase.
Keeling DJ; Malcolm RC; Laing SM; Ife RJ; Leach CA
Biochem Pharmacol; 1991 Jun; 42(1):123-30. PubMed ID: 1648919
[TBL] [Abstract][Full Text] [Related]
3. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
Nishioka K; Nagao T; Urushidani T
Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
[TBL] [Abstract][Full Text] [Related]
4. Sulfide and sulfoxide derivatives of substituted benzimidazoles inhibit acid formation in isolated gastric glands by different mechanisms.
Fryklund J; Wallmark B
J Pharmacol Exp Ther; 1986 Jan; 236(1):248-53. PubMed ID: 3001289
[TBL] [Abstract][Full Text] [Related]
5. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability.
Beil W; Staar U; Sewing KF
Eur J Pharmacol; 1992 Aug; 218(2-3):265-71. PubMed ID: 1330598
[TBL] [Abstract][Full Text] [Related]
6. (H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
Kohl B; Sturm E; Senn-Bilfinger J; Simon WA; Krüger U; Schaefer H; Rainer G; Figala V; Klemm K
J Med Chem; 1992 Mar; 35(6):1049-57. PubMed ID: 1313110
[TBL] [Abstract][Full Text] [Related]
7. Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell.
Wallmark B; Brändström A; Larsson H
Biochim Biophys Acta; 1984 Dec; 778(3):549-58. PubMed ID: 6095911
[TBL] [Abstract][Full Text] [Related]
8. Substituted thieno[3,4-d]imidazoles, a novel group of H+/K(+)-ATPase inhibitors. Differentiation of their inhibition characteristics from those of omeprazole.
Beil W; Staar U; Sewing KF
Eur J Pharmacol; 1990 Oct; 187(3):455-67. PubMed ID: 1963594
[TBL] [Abstract][Full Text] [Related]
9. BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions.
Kromer W; Postius S; Riedel R; Simon WA; Hanauer G; Brand U; Gönne S; Parsons ME
J Pharmacol Exp Ther; 1990 Jul; 254(1):129-35. PubMed ID: 2164086
[TBL] [Abstract][Full Text] [Related]
10. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.
Fujisaki H; Shibata H; Oketani K; Murakami M; Fujimoto M; Wakabayashi T; Yamatsu I; Yamaguchi M; Sakai H; Takeguchi N
Biochem Pharmacol; 1991 Jul; 42(2):321-8. PubMed ID: 1650210
[TBL] [Abstract][Full Text] [Related]
11. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
12. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.
Nagaya H; Satoh H; Kubo K; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):799-805. PubMed ID: 2537417
[TBL] [Abstract][Full Text] [Related]
13. Omeprazole, a specific inhibitor of gastric (H+-K+)-ATPase, is a H+-activated oxidizing agent of sulfhydryl groups.
Im WB; Sih JC; Blakeman DP; McGrath JP
J Biol Chem; 1985 Apr; 260(8):4591-7. PubMed ID: 2985559
[TBL] [Abstract][Full Text] [Related]
14. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor.
Morii M; Takata H; Fujisaki H; Takeguchi N
Biochem Pharmacol; 1990 Feb; 39(4):661-7. PubMed ID: 2154989
[TBL] [Abstract][Full Text] [Related]
15. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
Mattsson JP; Väänänen K; Wallmark B; Lorentzon P
Biochim Biophys Acta; 1991 Jun; 1065(2):261-8. PubMed ID: 1647821
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of (H+ + K+)-ATPase and H+ accumulation in hog gastric membranes by trifluoperazine, verapamil and 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate.
Im WB; Blakeman DP; Mendlein J; Sachs G
Biochim Biophys Acta; 1984 Feb; 770(1):65-72. PubMed ID: 6320882
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory action of omeprazole on acid formation in gastric glands and on H+,K+-ATPase isolated from human gastric mucosa.
Elander B; Fellenius E; Leth R; Olbe L; Wallmark B
Scand J Gastroenterol; 1986 Apr; 21(3):268-72. PubMed ID: 3012768
[TBL] [Abstract][Full Text] [Related]
18. The sulphoxide moiety of substituted benzimidazoles is essential for inhibition of parietal cell K+/H+-ATPase.
Beil W; Eltze M; Heintze K; Klemm K; Riedel R; Schudt C; Sewing KF; Simon A
Br J Pharmacol; 1986 Jun; 88(2):389-95. PubMed ID: 3015311
[TBL] [Abstract][Full Text] [Related]
19. Studies on the mechanism of action of the gastric microsomal (H+ + K+)-ATPase inhibitors SCH 32651 and SCH 28080.
Scott CK; Sundell E; Castrovilly L
Biochem Pharmacol; 1987 Jan; 36(1):97-104. PubMed ID: 3026407
[TBL] [Abstract][Full Text] [Related]
20. Studies on the mechanism of action of omeprazole.
Keeling DJ; Fallowfield C; Milliner KJ; Tingley SK; Ife RJ; Underwood AH
Biochem Pharmacol; 1985 Aug; 34(16):2967-73. PubMed ID: 2992525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
